However, NRF2 activation in tumor cells or virally infected cells induces IL-17D and thereby potentiating anti-tumor immunity and antiviral immunity against vaccina virus (VV) and mouse cytomegalovirus (MCMV) [135]. Here, IL17D is linked to neoplasm.